A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
|Articles|September 24, 2014
PHT's eDiary System Selected by Agile Therapeutics for Phase III Trial
PHT Corporation announced its LogPad System has been selected by Agile Therapeutics for use
Advertisement
PHT Corporation, a provider of technologies used to collect patient-driven eData for clinical research, says that its LogPad® System has been selected by Agile Therapeutics for use in its SECURE Phase III trial for its investigational product candidate, Twirla®. Agile's Senior VP of Clinical Development noted it chose the LogPad System for its proven track record of data quality and security, and comfort and convenience for patients, as well as PHT's leadership, experience and excellent customer service.
Read the full release
Advertisement
Related to this article
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system integration not models, and how regulators across three jurisdictions are formalizing patient input requirements.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Why clinical development’s next AI bottleneck is not the model, but the system around it.
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more than sourcing strategy, and how early readiness signals predict trial risk.
FDA Opens Applications for Expedited IND Pilot Designed to Accelerate First-in-Human Trial Timelines
The pilot pairs drug sponsors with qualified research institutions to compress the path from drug identification to first-in-human study through rolling submission review and earlier coordination of institutional review board and site activation activities.
A Syneos Health-announced study from Tufts Center for the Study of Drug Development finds no single sourcing model consistently outperforms others, pointing instead to vendor coordination, governance, and fit-for-purpose design as the real performance drivers.
Regulatory expectations for patient input in drug development have shifted from aspiration to documented methodology across three major jurisdictions.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Lessons from Hundreds of Clinical Trials: AI’s Successes, Gaps, and Opportunities
2
The Execution Gap: Why Clinical Trial Infrastructure Has to Be Built Before AI Can Deliver
3
Benchmarking Study Finds Clinical Trial Performance Is Shaped by Operating Model Design, Not Sourcing Strategy
4
What "Patient Voice" Actually Requires: Beyond the Buzzword
5